US 11,365,394 C1 (13,059th)
Enhanced immune effector cells and use thereof
Bahram Valamehr, San Diego, CA (US); Ryan Bjordahl, San Diego, CA (US); Jode Goodridge, San Diego, CA (US); and Tom Tong Lee, San Diego, CA (US)
Filed by Fate Therapeutics, Inc., San Diego, CA (US)
Assigned to FATE THERAPEUTICS, INC., San Diego, CA (US)
Reexamination Request No. 90/019,502, May 2, 2024.
Reexamination Certificate for Patent 11,365,394, issued Jun. 21, 2022, Appl. No. 17/180,585, Feb. 19, 2021.
Application 17/146,200 is a division of application No. 16/579,411, filed on Sep. 19, 2019, granted, now 10,927,346.
Application 90/019,502 is a continuation of application No. 17/146,200, filed on Jan. 11, 2021.
Application 16/579,411 is a continuation of application No. PCT/US18/67289, filed on Dec. 21, 2018.
Claims priority of provisional application 62/774,052, filed on Nov. 30, 2018.
Claims priority of provisional application 62/649,781, filed on Mar. 29, 2018.
Claims priority of provisional application 62/609,827, filed on Dec. 22, 2017.
Ex Parte Reexamination Certificate issued on Oct. 16, 2025.
Int. Cl. C12N 5/0783 (2010.01); A61K 35/545 (2015.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); C07K 14/735 (2006.01); C07K 16/28 (2006.01); C12N 5/074 (2010.01); C12N 5/0789 (2010.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01); A61K 40/50 (2025.01)
CPC C12N 5/0696 (2013.01) [A61K 35/545 (2013.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/4222 (2025.01); A61K 45/06 (2013.01); C07K 14/70535 (2013.01); C07K 16/2896 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); C12N 5/0647 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); A61K 40/50 (2025.01); C12N 2310/20 (2017.05); C12N 2506/45 (2013.01); C12N 2800/80 (2013.01)]
AS A RESULT OF REEXAMINATION, IT HAS BEEN DETERMINED THAT:
Claim 1 is determined to be patentable as amended.
Claims 2-4, 7-13 and 16-20, dependent on an amended claim, are determined to be patentable.
New claim 21 is added and determined to be patentable.
Claims 5, 6, 14 and 15 were not reexamined.
1. A cell or a population thereof, wherein the cell is a human NK cell that comprises a [ bi-allelic genomic knockout of ] CD38 knockout [ , and wherein the human NK cell is capable of recruiting T cells] .
[ 21. The cell or population thereof of claim 1, wherein the human NK cell is capable of recruiting the T cells to a tumor site.]